BioVersys AG

📍 Basel, Switzerland🗓 Founded 2010👥 23 employees💰 Last funded Mar 2013
Biotechnology Research🌐 bioversys.com
Website LinkedIn
BioVersys AG is a privately-owned clinical stage Swiss pharmaceutical company focusing on research and development of small molecules acting on novel bacterial targets with applications in antimicrobial resistance (AMR) and targeted microbiome modulation. With the company’s award-winning TRIC technology we can overcome resistance mechanisms, block virulence production and directly affect the pathogenesis of harmful bacteria, towards the identification of new treatment options in the antimicrobial and microbiome fields. By this means, BioVersys addresses the high unmet medical need for new treatments against life-threatening resistant bacterial infections and bacteria-exacerbated chronic inflammatory microbiome disorders. Our most advanced research and development programmes address nosocomial infections of Acinetobacter baumannii (BV100, Phase 2), and tuberculosis (BVL-GSK098, Phase 2) in collaboration with GlaxoSmithKline (GSK) and a consortium of the University of Lille. BioVersys is located in the TechPark in the thriving biotech hub of Basel.
1
Total investors
0
Early stage
1
Mid stage
0
Late stage
2010
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Germany
1
Frequently asked questions
Who invested in BioVersys AG?
BioVersys AG has 1 investors on record on gritt.io, 1 mid-stage.
When did BioVersys AG last raise funding?
The most recent investment in BioVersys AG recorded on gritt.io was in March 2013.
When was BioVersys AG founded?
BioVersys AG was founded in 2010.
What industry is BioVersys AG in?
BioVersys AG operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is BioVersys AG based?
BioVersys AG is headquartered in Basel, Switzerland.